Can carcinogenic potency be predicted from in vivo genotoxicity data? a meta-analysis of historical data

Environmental and Molecular Mutagenesis

Volumn 52, Issue 7, 2011, Pages 518-528

  Hernández, Lya G ^a   Slob, Wout ^a,b   van Steeg, Harry ^a   van Benthem, Jan ^a  

^a NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

^b UTRECHT UNIVERSITY   (Netherlands)

Author keywords

Benchmark dose; Carcinogenicity; Comet assay; In vivo genotoxicity tests; Micronucleus; Quantitative analysis; Transgenic rodent mutation assay

Indexed keywords

ANALYTIC METHOD; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CARCINOGENESIS; CARCINOGENICITY; CHROMOSOME ABERRATION; CLINICAL PROTOCOL; CONTROLLED STUDY; DISEASE ASSOCIATION; GENE MUTATION; GENOTOXICITY; IN VIVO STUDY; MEDICAL LITERATURE; MICRONUCLEUS; MOUSE; MUTATION ASSAY; NONHUMAN; QUANTITATIVE ANALYSIS; RODENT; VALIDATION PROCESS;

ANIMALS; CARCINOGENS; COMET ASSAY; MICE; MICRONUCLEUS TESTS; MUTAGENICITY TESTS; RATS;

MUS; RODENTIA;

EID: 79960972994     PISSN: 08936692     EISSN: 10982280     Source Type: Journal    
DOI: 10.1002/em.20651     Document Type: Article

References (41)

1. Blakey DH, Douglas GR, Huang KC, Winter HJ. 1995. Cytogenetic mapping of lambda gt10 lacZ sequences in the transgenic mouse strain 40.6 (Muta Mouse). Mutagen 10: 145-148.
2. Burlinson B, Tice RR, Speit G, Agurell E, Brendler-Schwaab SY, Collins AR, Escobar P, Honma M, Kumaravel TS, Nakajima M, et al. 2007. Fourth International Workgroup on Genotoxicity testing: Results of the in vivo Comet assay workgroup. Mutat Res 627: 31-35.
3. Cohen SM. 2004. Human carcinogenic risk evaluation: An alternative approach to the two-year rodent bioassay. Toxicol Sci 80: 225-229.
4. Collins AR, Oscoz AA, Brunborg G, Gaivao I, Giovannelli L, Kruszewski M, Smith CC, Stetina R. 2008. The comet assay: Topical issues. Mutagen 23: 143-151.
5. Crump KS. 1984. A new method for determining allowable daily intakes. Fundam Appl Toxicol 4: 854-871.
6. Eastmond DA, Hartwig A, Anderson D, Anwar WA, Cimino MC, Dobrev I, Douglas GR, Nohmi T, Phillips DH, Vickers C. 2009. Mutagenicity testing for chemical risk assessment: Update of the WHO/IPCS Harmonized Scheme. Mutagen 24: 341-349.
7. EC. 2006. Regulation (EC) No 1907/2006 of the European Parliament and of the Council of 18 December 2006 concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals (REACH), establishing a European Chemicals Agency, amending Directive 1999/45/EC and repealing Council Regulation (EEC) No 793/93 and Commission Regulation (EC) No 1488/94 as well as Council Directive 76/769/EEC and Commission Directive 91/155/EEC, 93/67/EEC, 93/105/EC and 2000/21/EC.
8. EFSA. 2009. European Food Safety Authority. Guidance of the scientific committee on use of the benchmark dose approach in risk assessment. EFSA J 1150: 1-72.
9. Gold LS, Slone TH, Ames BN. 1998. What do animal cancer tests tell us about human cancer risk? Overview of analyses of the carcinogenic potency database. Drug Metab Rev 30: 359-404.
10. Gold LS, Slone TH, Bernstein L. 1989. Summary of carcinogenic potency and positivity for 492 rodent carcinogens in the carcinogenic potency database. Environ Health Perspect 79: 259-272.
11. Gold LS, Slone TH, Manley NB, Garfinkel GB, Hudes ES, Rohrbach L, Ames BN. 1991. The Carcinogenic Potency Database: analyses of 4000 chronic animal cancer experiments published in the general literature and by the U.S. National Cancer Institute/National Toxicology Program. Environ Health Perspect 96: 11-15.
12. Gossen JA, de Leeuw WJ, Tan CH, Zwarthoff EC, Berends F, Lohman PH, Knook DL, Vijg J. 1989. Efficient rescue of integrated shuttle vectors from transgenic mice: A model for studying mutations in vivo. Proc Natl Acad Sci USA 86: 7971-7975.
13. Hamada S, Sutou S, Morita T, Wakata A, Asanami S, Hosoya S, Ozawa S, Kondo K, Nakajima M, Shimada H, et al. 2001. Evaluation of the rodent micronucleus assay by a 28-day treatment protocol: Summary of the 13th Collaborative Study by the Collaborative Study Group for the Micronucleus Test (CSGMT)/Environ Mutagen Society of Japan (JEMS)-Mammalian Mutagenicity Study Group (MMS). Environ Mol Mutagen 37: 93-110.
14. Harbach PR, Zimmer DM, Filipunas AL, Mattes WB, Aaron CS. 1999. Spontaneous mutation spectrum at the lambda cII locus in liver, lung, and spleen tissue of Big Blue transgenic mice. Environ Mol Mutagen 33: 132-143.
15. Hartmann A, Agurell E, Beevers C, Brendler-Schwaab S, Burlinson B, Clay P, Collins A, Smith A, Speit G, Thybaud V, et al. 2003. Recommendations for conducting the in vivo alkaline Comet assay. 4th International Comet Assay Workshop. Mutagen 18: 45-51.
16. Heddle JA, Hite M, Kirkhart B, Mavournin K, MacGregor JT, Newell GW, Salamone MF. 1983. The induction of micronuclei as a measure of genotoxicity. A report of the U.S. Environmental Protection Agency Gene-Tox Program. Mutat Res 123: 61-118.
17. ICH. 2007. The International Conference on Harmonization of technical requirements of pharmaceuticals for human use (ICH). Available at.
18. Jacobson-Kram D, Sistare FD, Jacobs AC. 2004. Use of transgenic mice in carcinogenicity hazard assessment. Toxicol Pathol 32 Suppl 1: 49-52.
19. Jakubczak JL, Merlino G, French JE, Muller WJ, Paul B, Adhya S, Garges S. 1996. Analysis of genetic instability during mammary tumor progression using a novel selection-based assay for in vivo mutations in a bacteriophage lambda transgene target. Proc Natl Acad Sci USA 93: 9073-9078.
20. Kavlock RJ, Schmid JE, Setzer RWJr. 1996. A simulation study of the influence of study design on the estimation of benchmark doses for developmental toxicity. Risk Anal 16: 399-410.
21. Kirkland D, Speit G. 2008. Evaluation of the ability of a battery of three in vitro genotoxicity tests to discriminate rodent carcinogens and non-carcinogens III. Appropriate follow-up testing in vivo. Mutat Res 654: 114-132.
22. Kohler SW, Provost GS, Fieck A, Kretz PL, Bullock WO, Putman DL, Sorge JA, Short JM. 1991a. Analysis of spontaneous and induced mutations in transgenic mice using a lambda ZAP/lacI shuttle vector. Environ Mol Mutagen 18: 316-321.
23. Kohler SW, Provost GS, Fieck A, Kretz PL, Bullock WO, Sorge JA, Putman DL, Short JM. 1991b. Spectra of spontaneous and mutagen-induced mutations in the lacI gene in transgenic mice. Proc Natl Acad Sci USA 88: 7958-7962.
24. Kohler SW, Provost GS, Kretz PL, Fieck A, Sorge JA, Short JM. 1990. The use of transgenic mice for short-term, in vivo mutagenicity testing. Genet Anal Tech Appl 7: 212-218.
25. Lambert IB, Singer TM, Boucher SE, Douglas GR. 2005. Detailed review of transgenic rodent mutation assays. Mutat Res 590(1-3): 1-280.
26. Lambert IB, Singer TM, Boucher SE, Douglas GR. 2008. Detailed review paper on transgenic rodent mutation assays.OECD (Organization for Economic Co-operation and Development) Environment, Health and Safety Publications Series on Testing and Assessment (under review).
27. Nesslany F, Zennouche N, Simar-Meintieres S, Talahari I, Nkili-Mboui EN, Marzin D. 2007. In vivo Comet assay on isolated kidney cells to distinguish genotoxic carcinogens from epigenetic carcinogens or cytotoxic compounds. Mutat Res 630(1-2): 28-41.
28. Nohmi T, Katoh M, Suzuki H, Matsui M, Yamada M, Watanabe M, Suzuki M, Horiya N, Ueda O, Shibuya T, et al. 1996. A new transgenic mouse mutagenesis test system using Spi- and 6-thioguanine selections. Environ Mol Mutagen 28: 465-470.
29. Nohmi T, Suzuki M, Masumura K, Yamada M, Matsui K, Ueda O, Suzuki H, Katoh M, Ikeda H, Sofuni T. 1999. Spi(-) selection: An efficient method to detect gamma-ray-induced deletions in transgenic mice. Environ Mol Mutagen 34: 9-15.
30. OECD. 1997. Organization for Economic Co-operation and Development (OECD), Guideline for the Testing of Chemicals: Mammalian Erythrocyte Micronucleus Test (OECD TG 474). Organization for Economic Co-operation and Development, Paris.
31. OECD. 2008a. Draft OECD guideline for the testing of chemicals. Test Guideline 451: Carcinogenicity studies. Available at.
32. OECD. 2008b. Organization for Economic Co-operation and Development (OECD), Draft OECD Guideline for the testing of chemicals. Test Guideline 453: Combined Chronic Toxicity\Carcinogenicity Studies. Available at.
33. Piersma AH, Verhoef A, te Biesebeek JD, Pieters MN, Slob W. 2000. Developmental toxicity of butyl benzyl phthalate in the rat using a multiple dose study design. Reprod Toxicol 14: 417-425.
34. Sanner T, Dybing E. 2005. Comparison of carcinogenic and in vivo genotoxic potency estimates. Basic Clin Pharmacol Toxicol 96: 131-139.
35. Slob W. 2002. Dose-response modeling of continuous endpoints. Toxicol Sci 66: 298-312.
36. Slob W, Moerbeek M, Rauniomaa E, Piersma AH. 2005. A statistical evaluation of toxicity study designs for the estimation of the benchmark dose in continuous endpoints. Toxicol Sci 84: 167-185.
37. Slob W, Pieters MN. 1997. Few, large, or many small dose groups? An evaluation of toxicological study designs using computer simulations RIVM Report, No. 620 110 006. The National Institute of Public Health and the Environment, Bilthoven, The Netherlands.
38. Tice RR, Agurell E, Anderson D, Burlinson B, Hartmann A, Kobayashi H, Miyamae Y, Rojas E, Ryu JC, Sasaki YF. 2000. Single cell gel/comet assay: Guidelines for in vitro and in vivo genetic toxicology testing. Environ Mol Mutagen 35: 206-221.
39. Tuo J, Loft S, Thomsen MS, Poulsen HE. 1996. Benzene-induced genotoxicity in mice in vivo detected by the alkaline comet assay: Reduction by CYP2E1 inhibition. Mutat Res 368(3-4): 213-219.
40. Vijg J, Dolle ME, Martus HJ, Boerrigter ME. 1997. Transgenic mouse models for studying mutations in vivo: Applications in aging research. Mech Ageing Dev 99: 257-271.
41. Woutersen RA, Jonker D, Stevenson H, te Biesebeek JD, Slob W. 2001. The benchmark approach applied to a 28-day toxicity study with Rhodorsil Silane in rats. The impact of increasing the number of dose groups. Food Chem Toxicol 39: 697-707.